Atyr Pharma Inc’s filing revealed that its Director SCHIMMEL PAUL acquired Company’s shares for reported $0.1 million on Jul 24 ’24. In the deal valued at $1.93 per share,52,300 shares were bought. As a result of this transaction, SCHIMMEL PAUL now holds 413,023 shares worth roughly $1.36 million.
Then, SCHIMMEL PAUL bought 41,052 shares, generating $71,500 in total proceeds. Upon buying the shares at $1.74, the Director now owns 354,075 shares.
Before that, SCHIMMEL PAUL bought 6,648 shares. Atyr Pharma Inc shares valued at $12,075 were divested by the Director at a price of $1.82 per share. As a result of the transaction, SCHIMMEL PAUL now holds 360,723 shares, worth roughly $1.19 million.
Cantor Fitzgerald initiated its Atyr Pharma Inc [ATYR] rating to an Overweight in a research note published recently. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early October with a ‘”an Overweight”‘ rating. Jefferies began covering ATYR with “Buy” recommendation on September 05, 2024. Oppenheimer revised its rating on July 05, 2023. It rated ATYR as “a Perform” which previously was an “an Outperform”.
Price Performance Review of ATYR
On Monday, Atyr Pharma Inc [NASDAQ:ATYR] saw its stock fall -6.80% to $3.29. Over the last five days, the stock has lost -17.34%. Atyr Pharma Inc shares have fallen nearly -9.12% since the year began. Nevertheless, the stocks have risen 106.92% over the past one year. While a 52-week high of $4.22 was reached on 01/06/25, a 52-week low of $1.39 was recorded on 01/13/25. SMA at 50 days reached $3.33, while 200 days put it at $2.25.
Levels Of Support And Resistance For ATYR Stock
The 24-hour chart illustrates a support level at 3.19, which if violated will result in even more drops to 3.09. On the upside, there is a resistance level at 3.44. A further resistance level may holdings at 3.60. The Relative Strength Index (RSI) on the 14-day chart is 44.22, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.13, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 85.39%. Stochastics %K at 38.06% indicates the stock is a holding.
How much short interest is there in Atyr Pharma Inc?
A steep rise in short interest was recorded in Atyr Pharma Inc stocks on 2024-12-13, growing by 0.81 million shares to a total of 2.92 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 2.11 million shares. There was a rise of 27.59%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 12, 2021 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $22 price target.
